I'm with you timkiely, I largely made my investment based on the track record and good reputation of Alan Gray in the biotech space. I also took their involvement and participation in the most recent rights issue as a good sign. I would be surprised if they did not play a part in the recent board changes as they appear to be as caught off guard as the rest of the retail SHs.